dcsimg Aranesp® (darbepoetin alfa) – Dosing Options
› Email› Print

Aranesp® offers multiple dosing and administration options

Once weekly. Once every 2 weeks. Once every 4 weeks.

The intravenous route of administration is recommended for patients on HD

Once weekly. Once every 2 weeks. Once every 4 weeks.

Important Safety Information

  • Use caution in patients with coexistent cardiovascular disease and stroke.
  • Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. A rate of hemoglobin rise of > 1 g/dL over 2 weeks may contribute to these risks.

Scroll down for additional Important Safety Information

Abbreviations and References:
ESA = erythropoiesis-stimulating agent; HD = hemodialysis; PD = peritoneal dialysis; QW = once weekly; Q2W = once every 2 weeks; Q4W = once every 4 weeks.
UltraSafe® is a registered trademark of Safety Syringes, Inc.
Reference: 1. Safety Syringes, Inc. 2007. Available at: http://www.safetysyringes.com/pdf/25-NG_English2007cfo.pdf. Accessed August 1, 2013.

Biotechnology by Amgen®